ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2809

Human Papilloma Virus and Chlamydia Trachomatis Infections in Rheumatoid Arthitis Under Anti-TNF Therapy

Mariana G Waisberg1, Ana C.M. Ribeiro2, Wellington M. Candido1, Poliana B. Medeiros1, Cezar N. Matsuzaki3, Mariana C. Beldi1, Maricy Tacla1, Helio H. Caiaffa-Filho4, Eloisa Bonfá1 and Clovis A Silva5, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 3Gynecology Department, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4Central Laboratory Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 5Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: infection and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cervical human papillomavirus (HPV) infection has been observed in 28% of rheumatoid arthritis (RA) patients in a cross-sectional study with no available data regarding Chlamydia trachomatis (CT) infection. Anti-TNF blockage may increase the risk of these gynecologic complications, in spite of a few case reports of HPV infection in chronic inflammatory arthritis and psoriasis under this therapy. Therefore, the purpose of our study was to evaluate HPV and CT infections in RA patients pre- and 6 months post-TNF blocker. The possible associations among these infections, demographic data, sexual function, disease parameters and treatment were also analyzed.

Methods: Fifty female RA patients (ACR criteria), who were eligible to anti-TNF therapy, [n=50 at baseline (BL) and n=45 after 6 months of treatment (6M)] and 50 age-matched healthy controls were prospectively enrolled. All RA patients and controls had previous sexual activity. Exclusion criteria were: current pregnancy, early post-partum period, diabetes mellitus, psychiatric diseases and cervical cancer. They were assessed for demographic data, gynecologic, sexual, cervical cytology and histological evaluations, disease parameters and current treatment. HPV DNA and CT DNA testing in cervical specimens were done using Hybrid Capture II assays. 

Results: At BL, the median current age of RA patients and controls was 49(18-74) vs. 49(18-74) years, p=1.0. A trend of lower frequency of HPV infection was observed in AR patients pre anti-TNF compared to controls (14% vs. 30%, p=0.054). None of patients had genital warts. Further evaluation of AR patients with and without HPV infection before anti-TNF therapy showed that the former group had a higher frequency of sexual intercourses (100% vs. 48%, p=0.014), higher median number of sexual partners [1(1-1) vs. 0(0-1), p=0.032] and higher frequency of abnormal cervical cytology (43% vs. 7%, p=0.029). Current age, disease duration, physician and patient visual analogue scales, DAS 28, ESR, CRP and treatments were alike in both groups (p>0.05). At 6M after TNF blockage, HPV infection remained unchanged in five patients, whereas two became negative and one additional patient turn out to be positive (McNemar´s test p=1.0). None of them had cervical cancer in Pap smear. CT infection was uniformly negative in RA patients pre- and post-TNF blockage and in controls. 

Conclusion: To our knowledge, this was the first study to assess prospectively genital infections in RA patients under TNF blockage therapy. Anti-TNF does not seem to increase short-term risk or severity of HPV and CT infections in RA patients.


Disclosure:

M. G. Waisberg,
None;

A. C. M. Ribeiro,
None;

W. M. Candido,
None;

P. B. Medeiros,
None;

C. N. Matsuzaki,
None;

M. C. Beldi,
None;

M. Tacla,
None;

H. H. Caiaffa-Filho,
None;

E. Bonfá,

FAPESP 2009/51897-5, CNPq 301411/2009-3 and Federico Foundation,

2;

C. A. Silva,

FAPESP 2009/51897-5, CNPq 302724/2011-7 and Federico Foundation ,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-papilloma-virus-and-chlamydia-trachomatis-infections-in-rheumatoid-arthitis-under-anti-tnf-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology